The role of angiogenesis in supporting solid tumor growth is well known (1) . At the molecular level, tumor angiogenesis is mediated by a balance of activators and inhibitors. Activators include members of the vascular endothelial growth factor (VEGF) and fibroblast growth factor families, whereas inhibitors include thrombospondin-1, interferon ␣/␤, angiostatin, endostatin, and others (2) (3) (4) . There is ample evidence suggesting that VEGF is a major contributor to tumor angiogenesis and growth. For example, VEGF is a mitogen and chemoattractant for endothelial cells (EC) and an angiogenesis factor in vivo (5) (6) (7) . Most tumor cells produce high levels of VEGF, and VEGF receptors (VEGFRs) are expressed by tumor EC (5, 8, 9) . Tumor vascularization and growth are inhibited by anti-VEGF antibodies (10, 11) , by dominant-negative VEGFRs (12) , and by soluble VEGFRs (13, 14) . VEGF expression is induced by oncogenes such as Ras and inhibited by tumor suppressors such as von Hippel Landau protein (15) . VEGF expression is up-regulated by hypoxia and is often elevated in regions of tumor necrosis (16) .
VEGF activities are mediated by high-affinity receptor tyrosine kinases (RTKs) associated primarily with EC. Three VEGF binding RTKs have been identified, Flt-1 (VEGFR-1), KDR/Flk-1 (VEGFR-2), and Flt-4 (VEGFR-3). VEGFR-1 and VEGFR-2 are primarily expressed by vascular EC and VEGFR-3 by lymphatic EC (17) (18) (19) (20) . Recently, we identified another VEGFR, neuropilin-1 (NRP1) (21, 22) , which is expressed by EC and tumor cells. NRP1 binds VEGF 165 but not VEGF 121 since the NRP1 binding site in VEGF 165 is encoded by VEGF exon 7, a domain that is lacking in VEGF 121 (21, 23) . NRP1 had been first described as a cell surface glycoprotein expressed on axons in the developing nervous system (24, 25) and subsequently shown to be a receptor for the semaphorins/collapsins (26, 27) , a family of transmembrane and secreted glycoproteins that act as mediators of neuronal guidance (26, 28 -30) . Secreted collapsin-1 (Sema III/Sema D, now known as Sema 3A) binds to NRP1 on axons, repels neurons, and induces the collapse of dorsal root ganglia (DRG) neuronal growth cones (29) . Another member of the NRP family, NRP2, is a receptor for VEGF 165 , placental-derived growth factor-2 (22, 31) , and semaphorin IV (26, 27, 32) .
There is evidence that NRP1 mediates angiogenesis. Overexpression of NRP1 in mice resulted in excess capillary and blood vessel formation and hemorrhaging in embryos, contributing to embry-onic lethality (33) . Targeted disruption of NRP1 was embryonic lethal and exhibited various types of vascular defects including impairment of neural vascularization, transposition of large vessels, and insufficient development of vascular networks in the yolk sac (34, 35) . Our own studies demonstrated that coexpression of NRP1 and KDR in porcine aortic EC enhanced VEGF 165 binding to KDR and KDR-mediated chemotactic activity of VEGF 165 , suggesting that in EC, NRP1 acts as a coreceptor for KDR (22) . Furthermore, Sema 3A inhibited the motility of porcine aortic EC in an NRP1-dependent manner by disrupting the formation of lamellipodia and inducing depolymerization of F-actin (36) . VEGF 165 and Sema 3A are competitive inhibitors of each other in binding, EC motility, and DRG collapse assays (36) , suggesting that the two ligands have overlapping NRP1 binding sites, possibly the b/coagulation factor homology domain (32) .
An unanticipated result was our finding that tumor cells express NRP1 and bind VEGF 165 via that receptor (22) . Some tumor cell lines express abundant NRP1; for example, prostate and breast carcinoma cell lines possess 1-2 ϫ 10 5 NRP1 copies per cell. The K d of VEGF 165 binding to NRP1 in tumor cells is 2.8 ϫ 10 Ϫ10 M, approximately the same as for VEGF 165 binding to EC NRP1 (22) and Sema 3A binding to DRG NRP1 (26, 27) . Unlike EC, which express KDR as well as NRP1, the tumor cell lines we have examined do not express KDR or Flt-1. However, VEGF 165 binding to these cells is mediated by NRPs. The function of tumor-derived NRP1 is not known. Accordingly, we overexpressed NRP1 in tumor cells in vitro and in vivo using a tetracyclineinducible promoter to study the effect of NRP1 expression on tumor cell phenotype. We report here that conditional induction of NRP1 expression enhances tumor cell motility as well as VEGF 165 binding capacity in vitro. Furthermore, induced expression of NRP1 in vivo results in larger tumors associated with substantially increased tumor angiogenesis and a lesser degree of tumor cell apoptosis.
MATERIALS AND METHODS
VEGF 165 was a gift from Dr. Judith Abraham (Scios Inc., Sunnyvale, Calif.). Rat NRP1 cDNA in pMP21 vector and a rabbit polyclonal antibody directed against rat NRP1 were provided by Dr. Alex Kolodkin (Johns Hopkins University School of Medicine, Baltimore, Md.). Dunning rat prostate carcinoma cell lines AT2.1 and AT3.1 were provided by Dr. Bruce Zetter (Children's Hospital, Boston, Mass.) (37) . Materials were purchased from the following sources: cell culture media, Geneticin (G418), lipofectamine, Klenow DNA polymerase, and T4 DNA ligase (Life Technologies, Rockville, Md.); Taq DNA polymerase, dNTPs, hygromycin B, and protease inhibitors (Boehringer Mannheim, Indianapolis, Ind.); 3 H-thymidine, 125 I-sodium, 32 P-dCTP, and GeneScreenPlus hybridization transfer membranes (DuPont NEN, Boston, Mass.); disuccinimidyl suberate and IODO-BEADS (Pierce Chemical, Rockford, Ill.); DNA labeling kits (Amersham, Arlington Heights, Ill.). Restriction endonucleases were from New England Biolabs (Beverly, Mass.); X-ray films were from Eastman Kodak, Rochester, N.Y.; rabbit anti-von Willebrand factor (vWF) antibody and mouse monoclonal anti-proliferating cell nuclear antigen antibody were from DAKO (Carpinteria, Calif.); mouse monoclonal anti-VEGF antibody (Upstate Biotechnology, Lake Placid, N.Y.); Copenhagen rats were from Charles River Laboratories (Charlestown, Mass.). Doxycycline (Dox) and all other chemicals were from Sigma (St. Louis, Mo.) unless otherwise mentioned.
RNA extraction and reverse transcription-polymerase chain reaction (RT-PCR)
Total RNA was prepared from cells in culture using RNeasy columns (Qiagen, Santa Clarita, Calif.), according to the manufacturer's instructions. Reverse transcription of 2 g total RNA was carried out with Superscript II RNase H Ϫ reverse transcriptase and 200 ng random hexamers (Life Technologies). Primer pairs in PCR analysis were: 5ЈrNRP1 (ATGT-GGAAGTGATCGATGGAG), 3ЈrNRP1 (GCTATTGCGCTGT-CAGTGTAGA), 5Ј␤-actin (GACCTTCAACACCCCAGCC), 3Ј␤-actin (GCATACCCCTCGTAGATGG). PCR (25 cycles) was carried out in 30 l containing 10% of the cDNA from the RT reaction, 10 pmol of each primer, 0.2 mM dNTPs, and 1 U Taq DNA polymerase. Amplified PCR products (7 l) were electrophoresed on 1% agarose gels and stained with ethidium bromide.
Northern blot
NRP1 Northern blot analysis was carried out as described (22, 36) . Briefly, total RNA (15 g) was electrophoresed on 1% formaldehyde-agarose gels and transferred to GeneScreenPlus membranes. The membranes were hybridized (42°C, 18 h) using Hybridization Mixtures (Amresco, Solon, Ohio) with a 32 P-labeled fragment of rat NRP1 cDNA corresponding to nucleotides 400 -905 in the open reading frame. After hybridization, membranes were washed and exposed to X-ray films.
Tet-On system
AT2.1 cells were transfected with 5 g pTet-On (Clontech, Palo Alto, Calif.) and selected with 250 g/ml G418. To screen for induction in response to Dox, AT2.1/Tet-On cells were transiently cotransfected with pTRE-Luc and pLacZ. The luciferase activity was measured after 48 h induction with 2 g/ml Dox. LacZ activity was measured as a control for transfection efficiency. The pTRE plasmid DNA (Clontech) was linearized with XbaI and treated with Klenow DNA polymerase, followed by EcoRI digestion. A 3.4 kb rNRP1 cDNA was cut from pMP21-rNRP1 plasmid with XhoI (followed by Klenow polymerase treatment) and EcoRI digestions. The cDNA was ligated into pTRE with T4 DNA ligase, yielding pTRE-rNRP1. A clone of AT2.1/Tet-On with the highest luciferase activity was cotransfected with pTRE-rNRP1 and pTK-Hyg, yielding AT2.1/Tet-On/rNRP1 cells. The cells were grown in RPMI medium containing 10% Tet system approved fetal calf serum (Clontech), in the presence of hygromycin B and G418. Stable clones were screened for NRP1 expression by Northern and Western blot analyses after 48 h Dox induction. Mock transfectants were transfected with pTet-On, pTK-Hyg but without pTRE-rNRP1.
VEGF radioiodination and binding
The radioiodination of VEGF 165 (22, 36) was achieved using IODO-BEADS and specific activities ranging from 60,000 -90,000 cpm/ng were obtained. Binding assays with 10 ng/ml 125 I-VEGF 165 were carried out in 24-well plates using subconfluent cell cultures. The cells were lysed with 250 l of 1% Triton X-100 and bound radioactivity was measured in a gamma counter as described previously (22, 36) . Protein (5 l aliquots) was measured using a Bradford protein assay kit (Bio-Rad, Hercules, Calif.) and bound VEGF was normalized to cpm/g protein/well.
Western blot
Cell lysates (10 g) were resolved on 7.5% sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred to PVDF membranes (Millipore, Bedford, Mass.) as described (38) . Briefly, the membranes were blocked with 3% bovine serum albumin (BSA), incubated with rabbit anti-rat NRP1 (1:1000), washed with a wash buffer (20 mM Tris-HCl pH 7.4, 150 mM NaCl, 0.5% Tween-20), incubated with horseradish peroxidase (HRP) -conjugated goat anti-rabbit IgG antibody (1:5000, Boehringer Mannheim), and washed again. The proteins were detected with an ECL kit (NEN).
Motility assay
Motility assays were performed in a Boyden chamber (Neuro Probe Inc., Gaithersburg, Md.), as described previously (22, 36) . Briefly, 15,000 cells in serum-free RPMI medium containing 0.1% BSA were added to wells in the upper chamber and RPMI medium containing 0.1% BSA, but no growth factors were added to wells in the lower chamber. The membranes were fixed with 4% formaldehyde and the cells were stained with hematoxylin. The nonmigrating cells were scraped off from the top of the filter, and the migrated cells at the bottom side of the filter were counted by phase microscopy.
Proliferation assay
AT2.1/Tet-On/rNRP1 cells were seeded in 96-well plates (1000 cells/well).
3 H-Thymidine (1 Ci/well) was added when Dox treatment was started. After 48 h incubation, the cells were harvested and the thymidine incorporated into DNA was counted with a ␤-counter (38) .
Tumor growth in vivo
Animal studies were carried out in the animal facility of Children's Hospital in accordance with institutional guidelines. Male Copenhagen rats 2 months old were anesthetized with isoflurane inhalation. Cells (0.3ϫ10 6 /0.3 ml/rat) were injected subcutaneously (s.c.) at the dorsal site between two hind limbs. The rats (nϭ6, each group) were fed drinking water containing 1% sucrose. To induce NRP1 expression, 10 g/ml Dox was added to the drinking water, which was changed every 48 h. Tumor sizes were measured with a caliper every other day, and volume was determined with the formula, volume ϭ width 2 ϫ length ϫ 0.52 (39) .
Histology and histochemistry
Rats were killed 3-4 wk after tumor cell injection; tumor tissues were fixed with 4% paraformaldehyde in phosphatebuffered saline (PBS) and embedded in paraffin. Sections 5 m thick were examined by hematoxylin and eosin (H&E) staining. To examine entire tumor cross sections, slides were scanned with a Polaroid Sprint Scan35 scanner (Meyer Instruments). For immunostaining, tissue sections were deparaffinized and incubated with anti-rat NRP1 (1:1000), anti-vWF (1:1000), anti-PCNA (1:50), or anti-VEGF (1:50). The slides were washed with PBS, incubated with biotinylated goat anti-rabbit (for NRP1 and vWF) and biotinylated goat antimouse IgG (for PCNA and VEGF) (Vector Laboratories, Burlingame, Calif.). After HRP-Extravidin (1:50, Sigma) incubation, the immunohistological reaction products were visualized with 3,3Ј-diaminobenzidine. As controls, the primary antibodies were either omitted or replaced with normal IgGs. Apoptotic cells were detected with the terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) assay (40) . Briefly, the sections were incubated with biotin-11-dUTP and deoxynucleotidyl transferase (37°C, 16 h), washed, and incubated with HRP-Extravidin. The TUNEL-positive cells were revealed with stable 3,3Ј-diaminobenzidine (Research Genetics, Huntsville, Ala.).
RESULTS

Neuropilin-1 expression in rat prostate tumor cells
Dunning rat prostate carcinoma cell variants have been isolated that differ in cell motility and tumorigenicity (37). The AT3.1 cells are more motile and tumorigenic than AT2.1 cells. To confirm these cellular phenotypes, the two cell lines were analyzed in a Boyden chamber migration assay to determine basal motility levels and also injected into rats to measure tumor growth. AT3.1 cells were ϳthree or fourfold more motile than AT2.1 cells (Fig. 1A) . The volume of AT3.1 tumors in rats after 4 wk of growth was ϳ12-fold greater than that of the AT2.1 cell tumors (Fig. 1B) . Relative NRP1 expression in these cell lines was measured in vitro by RT-PCR and Northern blot analysis (Fig. 1C) . Whereas AT3.1 cells expressed abundant NRP1 mRNA, there was very little NRP1 expression by AT2.1 cells. In contrast, both cell types expressed similar levels of VEGF as determined by Northern blot analysis (Fig. 1C , bottom). Immunostaining of tumor sections demonstrated that NRP1 was produced in AT3.1 but not AT2.1 tumors (Fig. 1D ). NRP1-positive tumor cells were preferentially detected at the invading tumor front. Together, these results suggest there is a positive correlation between higher levels of NRP1 expression in tumor cells and enhanced tumor cell motility in vitro and tumor size in vivo.
Effects of NRP1 induction in AT2.1 cells in vitro
To show a direct effect of NRP1 expression on tumor cell phenotype, AT2.1 cells were transfected with rat NRP1 cDNA under the control of a tetracyclineinducible promoter (Fig. 2) . Two highly inducible clones, AT2.1/Tet-On/rNRP1 clones 10 and 12, were isolated in which NRP1 expression was strongly induced by the tetracycline analog Dox, as deter-mined by Northern blot ( Fig. 2A) and Western blot (Fig. 2B) analyses. NRP1 expression was weakly or not detectable in non-Dox-treated cells ( Fig. 2A , B, lanes 3, 5). However, in the presence of Dox, the levels of 3.4 kb NRP1 mRNA ( Fig. 2A, lanes 4, 6) and 130 kDa NRP1 protein (Fig. 2B , lanes 4, 6) were increased substantially. AT2.1 cells, mock-transfected with the pTet-On plasmid DNA but without NRP1 cDNA, did not express detectable NRP1 either in the presence ( Fig. 2A , B, lane 2) or absence of Dox ( Fig.  2A, B, lane 1) .The optimal dose of Dox necessary to induce NRP1 protein expression was 1-2 g/ml (not shown). NRP1 protein expression was detected at 24 h and was optimal 48 h after Dox treatment (not shown). NRP1 mRNA could be detected as early as 4 -6 h, and reached a maximum level at 20 -24 h after Dox treatment (not shown). VEGF mRNA levels were not altered by Dox treatments (not shown).
The induced NRP1 was functional.
125
I-VEGF 165 binding to AT2.1/Tet-On/rNRP1 clones 10 and 12 was increased ϳfour-to eightfold after Dox treatment (Fig. 3A) . Cross-linking followed by immunoprecipitation with specific anti-NRP1 antibodies also demonstrated the enhanced binding of Induction of NRP1 expression in AT2.1/Tet-On/ rNRP1 clones 10 and 12 increased cell basal level migration in a Boyden chamber ϳthreefold compared to mock-transfected controls (Fig. 3B) . The cell lines did not migrate to any greater extent in the presence of VEGF or fetal calf serum (data not shown). However, induction of NRP1 expression did not affect tumor cell proliferation as measured by 3 H-thymidine incorporation 48 h after Dox treatment (Fig. 3C) .
All of the results that were obtained using the Dox-inducible promoter system were also obtained using stable AT2.1 cell lines expressing NRP1 (not shown).
NRP1 expression promotes tumor angiogenesis and progression in vivo
AT2.1/Tet-On/rNRP1 clone 10 cells and the mocktransfected tumor cells were injected into rats s.c. The rats, six in each experimental and control group, were fed Dox in their drinking water over a 4 wk period and the kinetics of tumor growth was measured (Fig. 4A) . In the absence of Dox, AT2.1 clone 10 tumors grew to a volume of ϳ12 cm 3 ( Fig.  4A, open circles) . When NRP1 expression was induced by Dox, the tumor volume was ϳ28 cm 3 , a 2.5-fold increase in size (Fig. 4A, filled circles) . On the other hand, mock-transfected tumor cells grew as 2) and transfected clones 10, 12 (lanes 3-6) were grown in RPMI medium in the absence (lanes 1, 3, 5 ) and presence (lanes 2, 4, 6) of Dox (2 g/ml, 48 h). A) Northern blot. Total RNA was harvested and NRP1 expression was analyzed. Ethidium bromide staining of ribosomal RNA (28s) was a control for equal loading. B) Western blot. Lysates were resolved by a 7.5% SDS-PAGE; NRP1 expression was analyzed using anti-rNRP1 antibody. Arrowheads indicate NRP1.
tumors to a size of ϳ10 cm 3 whether the animals were fed Dox (Fig. 4A, filled squares) or not (Fig. 4A , open squares), demonstrating that Dox in itself has no effect on tumor growth in vivo.
Immunohistological staining with specific anti-NRP1 antibodies demonstrated that NRP1 protein expression was markedly induced by Dox (Fig. 4E ) compared to non-Dox controls (Fig. 4D) . As expected, Dox had no effect on NRP1 expression in mock-transfected tumor cells lacking NRP1 cDNA (Fig. 4C) . Tumors with induced NRP1 appeared to have more blood vessels compared to controls (Fig.  4E vs. D) . These blood vessels often appeared to be dilated. The presence of blood vessels was confirmed by immunostaining with anti-vWF antibody, a marker for EC. Tumors with induced NRP1 were significantly enriched in vWF-positive dilated microvessels (Fig. 4G vs. F) . The blood vessel number was quantitated by counting tumor vessels in five fields/tumor It was estimated that tumors with induced NRP-1 had three to four times more blood vessels than the control tumors.
To demonstrate reproducibility with another inducible-AT2.1 clone and to further examine the phenotype of the tumors with induced NRP1, AT2.1/Tet-On/rNRP1 clone 12 cells were grown in vivo. Tumor volumes were increased sevenfold in a 19 day period in animals that were fed Dox (Fig. 5A , filled circles) compared to untreated controls (Fig.  5A, open circles) . Upon termination of the experiment, whole tumor tissues were subjected to histological analysis. Tumors with induced NRP1 were visibly much larger than noninduced controls (Fig.  5A, insets) .
Tumors expressing induced NRP1 had much higher levels of PCNA-positive proliferating tumor cells (Fig. 5C) than noninduced tumors (Fig. 5B) . In addition, tumors with induced NRP1 also contained PCNA-positive vascular EC (Fig. 5C, inset) , indicating a higher level of EC proliferation compared to the controls. Tumors with induced NRP1 (Fig. 5E ) had relatively few apoptotic cells as determined by TUNEL staining. On the other hand, in non-Dox induced tumors (Fig. 5D ), there were numerous regions of apoptotic tumor cells. In addition, apoptotic vascular EC were detected in the non-Doxinduced tumors (Fig. 5D, inset) , whereas EC in tumors with induced NRP1 expression were mostly non-apoptotic (Fig. 5E, open arrow) . Since NRP1 is a VEGF receptor, tumor sections were immunostained with anti-VEGF antibodies to determine VEGF distribution. There was stronger VEGF immunostaining in tumors with induced NRP1 expression (Fig. 5G ) than the control tumors (Fig. 5F ). However, no difference was observed in mRNA expression levels when the sections were analyzed by in situ hybridization with VEGF riboprobes (not shown). These results suggest that the tumors overexpressing NRP1 do not synthesize additional VEGF but bind more VEGF to the tumor cells.
DISCUSSION
This report suggests a possibly novel function for tumor cell-derived NRP1 as a mediator of tumor angiogenesis. To ascertain the effect of NRP1 expression on tumor cell phenotype, NRP1 cDNA was placed under the direction of a tetracycline-inducible promoter. Induction of NRP1 expression in AT2.1 prostate carcinoma cells in vivo by feeding rats the tetracycline homologue doxycycline resulted in larger tumor volumes-ϳ2.5-fold with one clone and six-to sevenfold in a second clone in 3-4 wk compared to noninduced controls. Dox itself had no effect on tumor growth since mock-transfected tumor cells grew to the same extent with or without Dox. Overexpression of NRP1 in tumor cells appeared to enhance tumor angiogenesis. The NRP1-overexpressing tumors were substantially more vascular as determined by vWF staining. In addition, an increase in proliferating EC in tumors with induced NRP1 expression was detected by PCNA staining. Besides an apparent increase in blood vessel density, Fig. 2 . A) Cells were incubated with 125 I-VEGF 165 (10 ng/ml), washed, lysed, and 125 I-VEGF 165 bound to cell surface was measured with a gamma counter. Data shown are the mean Ϯ sd of cpm/g protein/well from four independent wells. B) Migration. Cells in serumfree RPMI medium containing 0.1% BSA were added to wells in the upper chamber of a Boyden chamber. Serum-free RPMI medium containing 0.1% BSA was added to the lower wells. The cells were incubated for 4 h at 37°C and cells migrated through the filter were counted. Data shown are the mean Ϯ sd of four replicates. C) Proliferation. Cells were seeded in 96-well plates (1000 cells/well) in RPMI medium containing 10% Tet-approved fetal calf serum.
3 H-Thymidine (1 Ci/well) was added at the same time as Dox. After 48 h, cells were harvested and thymidine incorporation into DNA was measured with a ␤-counter. Data shown are the mean Ϯ sd of six replicates.
the vessels in NRP1-overexpressing tumors were more dilated, suggesting possible increased blood flow in the tumors. NRP1 expression also decreased tumor cell and tumor vascular EC apoptosis in vivo, indicating a survival function for NRP1, possibly due to binding of VEGT and increased tumor vascularization.
These results indicate that tumor-derived NRP1 is functional. Previous results have shown that neuronal NRP1 mediates semaphorin axon repulsion activity (26, 27) and that EC-NRP1 acts as a coreceptor enhancing VEGFR-2-mediated chemotactic activities (22) . The mechanisms by which NRP1 expression induces tumor angiogenesis and tumor growth in vivo are not yet known. Dox-inducible NRP1 expression results in a five-to eightfold increase in VEGF 165 binding to NRP1-positive tumor cells in vitro, and greatly enhanced levels of VEGF protein, but not VEGF mRNA, can be detected in NRP1-overexpressing tumors in vivo. Thus, one plausible mechanism is that as a result of the enhanced levels of AT2.1 cell surface NRP1 after induction, the VEGF 165 produced by these cells is retained in the tumor rather than diffusing away and, as a consequence of higher concentrations of available VEGF 165 in the tumor, tumor angiogenesis is enhanced. The higher levels of NRP1 on tumor cells could also lead to the binding of other members of the VEGF family. VEGF-B and placental-derived growth factor, which are expressed in tumor cells, also bind to NRP1 (41, 42) and are angiogenic (43) .
There are alternative mechanisms as well; for example, VEGF 165 could stimulate tumor cells directly via NRP1. VEGF 165 binds to the AT2.1 prostate tumor cells via NRP1 in the absence of VEGF RTKs and could activate these tumor cells directly via a nonangiogenic pathway. One possibility is that NRP1 expression activates downstream contributors to migration pathways. For example, we have shown that Sema 3A inhibits EC migration by retracting lamellipodia and depolymerizing F-actin in a NRP1-dependent manner (36) similar to the mechanisms that lead to growth cone collapse (29) . These processes are regulated by members of the GTP binding protein family, including RhoA, Rac1, and Cdc42 (44), and they could conceivably play a role in NRP1-dependent tumor cell migration. It is now clear that VEGF 165 is not specific for EC but can interact with non-EC such as tumor cells (22) , Schwann cells (45, 46) , and bone marrow stromal cells (47) via NRP1. However, the effects of VEGF 165 on NRP1, a receptor with no apparent cytoplasmic kinase motifs, in these cell types are yet unknown.
It may also be that the effects of NRP1 overexpression on cell motility in vitro and tumor angiogenesis in vivo are VEGF 165 independent. The increase in tumor cell migration in a Boyden chamber in vitro after Dox induction of NRP1 was basal and not increased any further by stimulation with VEGF 165 , suggesting an NRP1 function independent of VEGF. One possibility is that NRP1 overexpression induces downstream genes that are responsible for enhancing cell motility and tumor vascularization. Analysis of NRP1-inducible genes after Dox induction of NRP1 is under way.
The proactive role of NRP1 in enhancing tumor angiogenesis and tumor growth suggests that antagonizing NRP1 activity in tumor cells may be a feasible anti-tumor strategy. We have previously identified several anti-NRP1 antagonists. One of these is soluble NRP1 (sNRP1), which consists of a portion of the NRP1 ectodomain and is expressed and secreted by PC3 human prostate carcinoma and other cell types (48) . Tumors overexpressing sNRP1 are hemorrhagic and full of disrupted blood vessels; the tumor cells are mostly apoptotic, a phenotype opposite of tumors overexpressing full-length NRP1 as reported here. A possible mechanism is that sNRP1 sequesters VEGF 165 away from EC, thereby blocking VEGFinduced tumor angiogenesis. Another potential NRP1 antagonist is Sema3A, which is a competitive inhibitor of VEGF 165 binding and of VEGF-induced EC migration (36) . Some tumor cells express NRP1, sNRP1, VEGF and, in preliminary studies, Sema3A (C. J. Choi, H.-Q. Miao, and M. Klagsbrun, unpublished results). It may be that the balance of these angiogenesis-mediating factors determines the angiogenic potential of a tumor cell.
In summary, this report is the first demonstration of NRP1 function in tumor cells. Tumor-derived NRP1 acts as a positive modulator of angiogenesis. Our future goals are to delineate the mechanisms by which NRP1 contributes to tumor growth and to target NRP1 as a potential anti-cancer strategy.
